Home » Newsletters » BioWorld Science

BioWorld Science

March 13, 2008

View Archived Issues

Recent patent literature discloses novel antibacterial agents

New therapeutic agents for obesity and other metabolic disorders described in recent patents

Novel therapeutic agents for HIV infection reported in a recent patent

Maruzen imparts novel agents for dermatological disorders in a recent patent

Experiments clarify antidepressant activity of ketamine

Significant antimanic effects observed with tamoxifen in a randomized trial

FDA accepts Pipex's IND application to conduct phase II clinical trial of oral flupirtine

Nventa initiates dosing in final cohort of phase I trial of HspE7

iCo Therapeutics presents a clinical update on human monoclonal antibody iCo-008

Anavex reports results from preclinical studies of cancer drug Anavex 7-1037

Symbollon signs term sheet to acquire MedPharm for USD 1.5 million

EUSA Pharma to acquire Cytogen for USD 22.6 million in cash

EMEA grants Clinuvel two orphan drug designations for CUV-1647

Percutaneous Loxonin Tape receives Japanese marketing approval

Novartis submits Rasilez for approval in Japan

CRx-191 demonstrates positive phase II results in psoriasis

Nymox reports results from U.S. NX-1207 study in benign prostatic hyperplasia

XenoPort presents positive phase I results with XP-21279

Bionovo reports support for MF-101 from two independent physician surveys

Ortho Biotech to defend the safety of Procrit and ESAs at meeting with the ODAC

Avicena's HD-02 to enter NIH-sponsored phase III trial in HD

Calistoga Pharmaceuticals begins first clinical trial of novel oral PI3K delta inhibitor

FDA accepts Arisaph's IND application to evaluate ARI-2243 in phase I clinical trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...